Features & Benefits

The QuantideX NGS RNA Lung Cancer Kit offers a unique NGS-in-a-Box™ solution that provides unprecedented NGS workflow efficiency and high sensitivity at low input amounts from precious FFPE NSCLC samples.

Reduced ComplexityAssay incorporates sample-to-data solutions in a unique NGS-in-a-Box™ configuration

• Single assay for a broad range of important NSCLC fusion targets
• All-inclusive reagents from reverse transcription to NGS-ready library
• Fully integrated data analysis pipeline

Optimized WorkflowEfficient workflow leads to lower operational costs and reduced hands-on and total turnaround time*

• Reduced labor vs. current commercially available kits
• Improved turnaround time enables higher throughput

^*Internal data on file.

Quality PerformanceHighly sensitive assay with integrated, Sample-Aware™ bioinformatics software and built-in quality checks to minimize erroneous results and sample failures

• Highly sensitive detection of RNA-based fusions
• Low input (~20ng) of RNA from FFPE
• Sample-Aware™ bioinformatics analysis and sample quality control

Product Description

Relevant ContentA focus on only the most important lung cancer fusion genes, MET exon 14 skipping events, 3’/5′ imbalances and mRNA expression from multiple published data sources such as COSMIC, ClinicalTrials.gov, NCCN Guidelines, etc.

• 107 NSCLC-relevant fusions
• ALK, RET, ROS1, and NTRK1 3’/5’ imbalances
• MET exon 14 skipping events (e13/e14; e14/e15; e13/e15)
• 23 mRNA targets, plus 3 endogenous control transcripts

A Fully Integrated WorkflowA unique NGS-in-a-Box™ configuration offers a simplified and fully integrated NGS workflow with cGMP-manufactured reagents, components and controls ready to run right out of the box.

Includes:

• RT-PCR reagents
• A unique RNA Lung Cancer Sample QC kit (QuantideX qPCR RNA Assay (Lung))
• Gene-specific PCR primers and Master Mix reagents
• Barcodes for sample multiplexing
• Library purification and quantification reagents
• Integrated data analysis and reporting software (QuantideX NGS Reporter)

Rapid & EfficientAdopt and run NGS-based analysis with minimum investment of time and resources, regardless of NGS experience and infrastructure.

• Fully integrated workflow reduces complexity and ensures reliable reagent quality
• Push-button analysis & reporting makes bioinformatics easy and efficient, regardless of experience level
• Integrated kit reduces workflow time by over 50% than competing NGS panels

Performance DataQuantideX NGS Assay is capable of detecting fusions and splice variants down to 1:100 cells. (a) Admixture of MET exon 14 positive cell line in the background of wild-type cells, and (b) fusion, and (c) 3’/5’ imbalance status for an admixture of EML4-ALK positive FFPE in the background of a negative FFPE.

Figure 3a

Figure 3b

Figure 3c

QuantideX® NGS Reporter

Push-button analytics & reporting suite – Set-up-and-go workflow designed for easy installation and implementation, right out of the box.

Runs directly on lab desktop – Install locally on a Windows® desktop computer. No prior bioinformatics experience or large server environments required.

Comprehensive reporting – Full bioinformatics and reporting of variants (SNVs, SNPs, Indels, fusions), and standard QC metrics are automatically calculated.

Integrates QuantideX RNA/DNA QC Assay – Sample-Aware™ bioinformatics with integrated functional template copy number analysis dramatically reduces false-call rates.

Seamless updates offered with new panel designs & variant annotation – Software updates allow new panels to be adopted without re-investing in analytics when the Asuragen QuantideX NGS product line is adopted.

Contact us to request the QuantideX Reporter

Resources

Videos

Posters

Accurate and Reproducible Detection of Fusions and Exon Skipping Events in NSCLC-Derived Samples Using A Comprehensive, Targeted RNA-Seq System Across Multiple LaboratoriesView full poster

Head-To-Head Comparison of Two Commercially Available Next-Generation Sequencing Technologies That Detect Gene Fusions In Non-Small Cell Lung CancerView full poster

A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung Cancer View full poster

Features & Benefits

The QuantideX NGS RNA Lung Cancer Kit offers a unique NGS-in-a-Box™ solution that provides unprecedented NGS workflow efficiency and high sensitivity at low input amounts from precious FFPE NSCLC samples.

Reduced ComplexityAssay incorporates sample-to-data solutions in a unique NGS-in-a-Box™ configuration

• Single assay for a broad range of important NSCLC fusion targets
• All-inclusive reagents from reverse transcription to NGS-ready library
• Fully integrated data analysis pipeline

Optimized WorkflowEfficient workflow leads to lower operational costs and reduced hands-on and total turnaround time*

• Reduced labor vs. current commercially available kits
• Improved turnaround time enables higher throughput

^*Internal data on file.

Quality PerformanceHighly sensitive assay with integrated, Sample-Aware™ bioinformatics software and built-in quality checks to minimize erroneous results and sample failures

• Highly sensitive detection of RNA-based fusions
• Low input (~20ng) of RNA from FFPE
• Sample-Aware™ bioinformatics analysis and sample quality control

Product Description

Relevant ContentA focus on only the most important lung cancer fusion genes, MET exon 14 skipping events, 3’/5′ imbalances and mRNA expression from multiple published data sources such as COSMIC, ClinicalTrials.gov, NCCN Guidelines, etc.

• 107 NSCLC-relevant fusions
• ALK, RET, ROS1, and NTRK1 3’/5’ imbalances
• MET exon 14 skipping events (e13/e14; e14/e15; e13/e15)
• 23 mRNA targets, plus 3 endogenous control transcripts

A Fully Integrated WorkflowA unique NGS-in-a-Box™ configuration offers a simplified and fully integrated NGS workflow with cGMP-manufactured reagents, components and controls ready to run right out of the box.

Includes:

• RT-PCR reagents
• A unique RNA Lung Cancer Sample QC kit (QuantideX qPCR RNA Assay (Lung))
• Gene-specific PCR primers and Master Mix reagents
• Barcodes for sample multiplexing
• Library purification and quantification reagents
• Integrated data analysis and reporting software (QuantideX NGS Reporter)

Rapid & EfficientAdopt and run NGS-based analysis with minimum investment of time and resources, regardless of NGS experience and infrastructure.

• Fully integrated workflow reduces complexity and ensures reliable reagent quality
• Push-button analysis & reporting makes bioinformatics easy and efficient, regardless of experience level
• Integrated kit reduces workflow time by over 50% than competing NGS panels

Performance DataQuantideX NGS Assay is capable of detecting fusions and splice variants down to 1:100 cells. (a) Admixture of MET exon 14 positive cell line in the background of wild-type cells, and (b) fusion, and (c) 3’/5’ imbalance status for an admixture of EML4-ALK positive FFPE in the background of a negative FFPE.

Figure 3a

Figure 3b

Figure 3c

QuantideX® NGS Reporter

Push-button analytics & reporting suite – Set-up-and-go workflow designed for easy installation and implementation, right out of the box.

Runs directly on lab desktop – Install locally on a Windows® desktop computer. No prior bioinformatics experience or large server environments required.

Comprehensive reporting – Full bioinformatics and reporting of variants (SNVs, SNPs, Indels, fusions), and standard QC metrics are automatically calculated.

Integrates QuantideX RNA/DNA QC Assay – Sample-Aware™ bioinformatics with integrated functional template copy number analysis dramatically reduces false-call rates.

Seamless updates offered with new panel designs & variant annotation – Software updates allow new panels to be adopted without re-investing in analytics when the Asuragen QuantideX NGS product line is adopted.

Contact us to request the QuantideX Reporter

Resources

Videos

Posters

Accurate and Reproducible Detection of Fusions and Exon Skipping Events in NSCLC-Derived Samples Using A Comprehensive, Targeted RNA-Seq System Across Multiple LaboratoriesView full poster

Head-To-Head Comparison of Two Commercially Available Next-Generation Sequencing Technologies That Detect Gene Fusions In Non-Small Cell Lung CancerView full poster

A Simple and Versatile Next-Generation Sequencing Technology for Co-Detection of RNA Structural Variants and DNA Mutations in Lung Cancer View full poster